Dexmedetomidine versus Remifentanil for Controlled Hypotension in surgery: A Narrative Review of Efficacy and Recovery Profiles

Dexmedetomidine and remifentanil are essential pharmacologic drugs that are now integral to anaesthetic practice, particularly for inducing controlled hypotension and enhancing intraoperative conditions. Dexmedetomidine, a selective α2-adrenoceptor agonist, is well known for its sedative and sympatholytic properties, with profound haemodynamic stability and minimal respiratory depression. Hence it is best suited for Intensive Care Unit (ICU) sedation and for opioid sparing strategies. It is beneficial in scenarios where earlier emergence from anaesthesia and prolonged sedation are advantageous. Remifentanil, a synthetic ultra short-acting opioid, has a rapid onset and offset, enabling precise titration and swift recovery, and is therefore well suited for fasttrack surgeries. Both drugs are effective in reducing intraoperative blood loss and in improving surgical field conditions through controlled hypotension. Nonetheless, remifentanil's faster onset may confer an advantage by achieving a clearer surgical field with less bleeding. While dexmedetomidine stands out for improving postoperative recovery with less pain and reduced opioid requirements, remifentanil stands out for more rapid recovery and shorter extubation times. The safety profiles of both drugs are favourable overall, with dexmedetomidine associated with bradycardia and remifentanil with nausea and shivering. This review discusses the pharmacological profiles, clinical use, safety issues and relative effectiveness of dexmedetomidine and remifentanil in controlled hypotension during surgery. It collects new information on their intraoperative haemodynamic impacts, recovery profiles, and patient-surgeon satisfaction measures in various surgical environments. One gap addressed is the absence of integrated clinical recommendations on choosing between the two agents, considering specific surgical and patient scenarios. By synthesising data from recent meta-analyses and randomised trials, the review highlights the clinical utility of drug selection as a function of surgery type, desired recovery profile and institutional practice patterns. Clinically significant guidance for anaesthesiologists and surgeons is provided by the results, with a view to maximising surgical field conditions while reducing undesirable outcomes, particularly in procedures where a bloodless field and haemodynamic stability are paramount.